<DOC>
	<DOCNO>NCT01190371</DOCNO>
	<brief_summary>The purpose study determine whether P. falciparum infection Kilifi District develop tolerance artemisinin class drug .</brief_summary>
	<brief_title>Have Malaria Infections Kenya Become Less Responsive Artemisinin Treatment ?</brief_title>
	<detailed_description>Artemisinin-based combination therapy ( ACT ) treatment choice episode uncomplicated P. falciparum malaria endemic country . Rapid clearance pathogenic blood stage malaria parasites artemisinins associate swift recovery mild malaria reduce mortality severe form disease . In Kenya , malaria endemic sub-saharan Africa , artemether-lumefantrine introduce first-line treatment public health care sector 2006 . Alarmingly , despite short time since introduction ACTs artemisinin-resistant P. falciparum malaria already emerge South-East Asia , area historically cradle global spread drug-resistant malaria parasite . In previous study Kilifi observe significant drop early response rate treatment two ACTs 2005 2008 . Conventional marker potential change anti-parasitic host immunity , drug exposure , baseline parasite biomass could account observed time-dependent change response rate . This protocol aim establish reasonable confidence whether P. falciparum infection Kilifi District develop tolerance artemisinin class drug . We propose study treatment response rate establish 7-day regimen artesunate alone treatment uncomplicated P. falciparum malaria child age 6 month 10 year , KEMRI study site Pingilikani , Kilifi District , Kenya . The study also assess ( ) pharmacokinetic parameter artesunate ; ( ii ) ex vivo vitro chemosensitivity parasite isolate DHA ; ( iii ) genetic determinant alter vivo vitro response DHA ; ( iv ) ex vivo expression profile normally vs. slowly respond P. falciparum infection treatment .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>age 6 month 10 year , inclusive monoinfection P. falciparum detect microscopy ; parasitaemia 10,000300,000/µl asexual form ; presence axillary temperature ≥ 37.5 °C history fever past 24 h ; ability swallow oral medication ; ability willingness comply study protocol duration study comply study visit schedule ; inform consent parent guardian . presence clinical danger sign : able drink breastfeed , vomit ( &gt; twice 24 hour ) , recent history convulsion ( &gt; 1 24h ) , unconscious state , unable sit stand ; mixed monoinfection another Plasmodium specie detect microscopy ; presence severe acute malnutrition define weight height &lt; 70 % median NCHS/WHO ( Appendix 2 ) ; presence febrile condition due disease malaria ( e.g . measles , acute low respiratory tract infection , severe diarrhoea dehydration ) know underlie chronic severe disease ( e.g . cardiac , renal hepatic disease , HIV/AIDS ) ; regular medication , may interfere antimalarial pharmacokinetics pharmacodynamic assessment ( e.g. , antibiotic know antimalarial activity ) ; history hypersensitivity reaction contraindication medicine ( ) test used alternative treatment ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Artemisinin tolerance</keyword>
</DOC>